Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allakos Inc ALLK

Healthcare Biotechnology
Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Company’s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively... see more

Recent & Breaking News (NDAQ:ALLK)

Allakos Announces Pricing of Public Offering of Common Stock

GlobeNewswire October 28, 2020

Allakos Previews Preliminary Financial Results for the Three Months Ended September 30, 2020

GlobeNewswire October 27, 2020

Allakos Announces Proposed Public Offering of Common Stock

GlobeNewswire October 27, 2020

Results from Prospective Prevalence Study Indicate that Eosinophilic Gastritis and Eosinophilic Duodenitis May be Significantly Underdiagnosed

GlobeNewswire October 26, 2020

Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)

GlobeNewswire October 26, 2020

Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine

GlobeNewswire October 21, 2020

Allakos Reports Second Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire August 10, 2020

SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of the Following Companies: Allakos, Inc. (Nasdaq - ALLK), Enphase Energy, Inc. (Nasdaq - ENPH), MoSys, Inc. (Nasdaq - MOSY)

ACCESSWIRE IA June 16, 2020

Allakos Initiates Patient Recruitment for AK002 Registrational Studies

GlobeNewswire June 3, 2020

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the Digital EAACI Annual Congress 2020

GlobeNewswire May 21, 2020

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Allakos Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile May 11, 2020

ALLK DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Allakos Inc. Investors of Class Action and Lead Plaintiff Deadline: May 11, 2020

ACCESSWIRE IA May 11, 2020

ALLAKOS FINAL DEADLINE TODAY: ROSEN, A GLOBALLY RECOGNIZED FIRM, Reminds Allakos Inc. Investors of Deadline Today In Securities Class Action First Filed by Firm - ALLK

Business Wire May 11, 2020

Allakos Announces a Presentation of Antolimab in Patients with Severe Allergic Conjunctivitis at the 2020 ASCRS Virtual Annual Meeting

GlobeNewswire May 11, 2020

Allakos Reports First Quarter 2020 Financial Results

GlobeNewswire May 11, 2020

DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Allakos Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile May 10, 2020

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Allakos (ALLK) Investors: Important Application Deadline Tomorrow, Investors with Losses Should Contact its Attorneys Now

ACCESSWIRE IA May 10, 2020

ALLK FINAL MONDAY DEADLINE, ROSEN, FIRST FILING FIRM AND GLOBAL COUNSEL, Encourages Allakos Inc. Investors to Contact Firm Prior to May 11 Deadline For Class Action Seeking Recovery of Investor losses - ALLK

ACCESSWIRE IA May 10, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allakos Inc. - ALLK

ACCESSWIRE IA May 10, 2020

FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA May 10, 2020